Download PDF
Klin Monbl Augenheilkd 2003; 220(12): 873-876
DOI: 10.1055/s-2003-812553
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

The - 429 T/C and - 374 T/A Gene Polymorphisms of the Receptor of Advanced Glycation End Products Gene are not Risk Factors for Diabetic Retinopathy in Caucasians with Type 2 Diabetes

Der - 429 T/C- und - 374 T/A-Gen-Polymorphismus des Rezeptors des „Advanced Glycation End Products Gene” stellt keinen Risikofaktor für die diabetische Retinopathie bei kaukasischen Diabetikern Typ 2 darMojca  Globočnik  Petrovič1 , Klemen  Steblovnik2 , Borut  Peterlin2 , Daniel  Petrovič3
  • 1Eye Clinic, University Medical Centre Ljubljana, Ljubljana, Slovenia
  • 2Division of Medical Genetics, Department of Obstetrics and Gynaecology, University Medical Centre Ljubljana, Ljubljana, Slovenia
  • 3Institute of Histology and Embryology, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
Further Information

Publication History

Eingegangen: 13. Mai 2003

Angenommen: 13. August 2003

Publication Date:
05 January 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hintergrund: Das Ziel dieser Studie war die Untersuchung der Beziehung zwischen den - 429 T/C und - 374 T/A Genpolymorphismen der Rezeptoren vom „advanced glycation end products” (RAGE)-Gen und der Entwicklung der diabetischen Retinopathie bei Kaukasiern mit Diabetes Typ II. Material und Methoden: 116 Patienten mit Diabetes Typ II und diabetischer Retinopathie wurden verglichen mit 70 Diabetikern ohne diabetische Retinopathie. Weiterhin wurden 76 Patienten mit proliferativer diabetischer Retinopathie (eine Untergruppe der diabetischen Retinopathie) verglichen mit 70 Diabetikern ohne diabetische Retinopathie. Ergebnisse: Die - 429 T/C und die - 374 T/A RAGE-Genverteilung bei Patienten mit diabetischer Retinopathie (- 429 T/C: CC 0,9 %, TC 29,9 %, TT 73 %, - 374 % T/A: AA 9,5 %, TA 47,4 %, TT 43,11) war nicht signifikant verschieden von der bei Diabetikern ohne diabetische Retinopathie (- 4,29 T/C: CC: 01, TC 25,71, TT 74,31; - 374 T/A: AA 15,71, TA 42,91, TT 41,41). Weiterhin war die - 429 T/C und die - 374 T/A RAGE-Gen-Verteilung bei Patienten mit proliferativer diabetischer Retinopathie statistisch nicht signifikant verschieden von der bei Diabetikern ohne Retinopathie. Schlussfolgerungen: Unsere Studie konnte keine Assoziation zwischen den - 429 T/C- bzw. - 374 T/A-Genpolymorphismus des RAGE-Gens und diabetischer Retinopathie bei Kaukasiern mit Diabetes Typ II feststellen. Ebenso konnte keine Assoziation zwischen - 429 T/C- bzw. - 374 T/A-Genpolymorphismus des RAGE-Gens und der proliferativen diabetischen Retinopathie bei Kaukasiern mit Diabetes Typ II aufgezeigt werden.

Abstract

Objective: The aim of this study was to look for a relationship between the - 429 T/C and the - 374 T/A gene polymorphisms of the receptor of advanced glycation end products (RAGE) gene and the development of diabetic retinopathy in Caucasians with type 2 diabetes. Materials and methods: One hundred and sixteen subjects with type 2 diabetes and diabetic retinopathy were compared to 70 diabetic subjects without diabetic retinopathy. Additionally, 76 subjects with proliferative diabetic retinopathy (a subgroup of diabetic retinopathy) were compared to 70 diabetic subjects without diabetic retinopathy. Results: The - 429 T/C and the - 374 T/A RAGE gene distributions in patients with diabetic retinopathy (- 429 T/C: CC 0.9 %, TC 25.9 %, TT 73.2 %; - 374 T/A: AA 9.5 %, TA 47.4 %, TT 43.1 %) were not significantly different from those of diabetic subjects without retinopathy (- 429 T/C: CC 0 %, TC 25.7 %, TT 74.3 %; - 374 T/A: AA 15.7 %, TA 42.9 %, TT 41.4 %). Moreover, the - 429 T/C and the - 374 T/A RAGE gene distributions in patients with proliferative diabetic retinopathy were not statistically significantly different from those in diabetic subjects without retinopathy. Conclusion: Our study failed to demonstrate an association between either - 429 T/C or - 374 T/A gene polymorphism of the RAGE gene and diabetic retinopathy in Caucasians with type 2 diabetes. Additionally, we failed to demonstrate an association between either - 429 T/C or - 374 T/A gene polymorphism of the RAGE gene and proliferative diabetic retinopathy in Caucasians with type 2 diabetes.

Schlüsselwörter

Rezeptor von „advanced glycation end products” Gen - - 429 T/C-Gen-Polymorphismus - - 374 T/A-Gen-Polymorphismus - diabetische Retinopathie - proliferative diabetische Retinopathie - Kaukasier - Diabetiker Typ 2 - genetische Risikofaktoren

Key words

Receptor of advanced glycation end products gene - - 429 T/C gene polymorphism - - 374 T/A gene polymorphism - diabetic retinopathy - proliferative diabetic retinopathy - Caucasians - type 2 diabetes - genetic risk factors

References

  • 1 Brownlee M. Advanced protein glycosylation in diabetes in aging.  Annu Rev Med. 1995;  46 223-234
    CrossrefPubMedSearch in Google Scholar
  • 2 Brownlee M. Biochemistry and molecular cell biology of diabetic complications.  Nature. 2001;  414 813-820
    CrossrefPubMedSearch in Google Scholar
  • 3 Early Treatment Diabetic Retinopathy Study Research Group . Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification ETDRS report number 10.  Ophthalmology. 1991;  98, Suppl 5 786-806
    CrossrefPubMedSearch in Google Scholar
  • 4 Hudson B I, Stickland M H, Futers T S, Grant P J. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy.  Diabetes. 2001;  50 1505-1511
    CrossrefPubMedSearch in Google Scholar
  • 5 Keen H, Lee E T, Russell D, Miki E, Bennett P H, Lu M. The appearance of retinopathy and progression to proliferative retinopathy: the WHO Multinational Study of Vascular Disease in Diabetes.  Diabetologia. 2001;  44, Suppl 2 22-30
    CrossrefPubMedSearch in Google Scholar
  • 6 Klein R, Klein B EK. Visual disorders. In: Harris CI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH (eds) Diabetes in America. Bethesda; National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases 1995: 293-338
    Search in Google Scholar
  • 7 Kumaramanickavel G, Ramprasad V L, Sripriya S, Upadyay N K, Paul P G, Sharma T. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients.  J Diabetes Complications. 2002;  16 391-394
    CrossrefPubMedSearch in Google Scholar
  • 8 Okamoto T, Yamagishi S, Inagaki Y. et al . Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.  FASEB J. 2002;  16 1928-1930
    PubMedSearch in Google Scholar
  • 9 Porta M, Sjoelie A K, Chaturvedi N. et al. for EURODIAB Prospective Complications Study Group . Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study.  Diabetologia. 2001;  44 2203-2209
    CrossrefPubMedSearch in Google Scholar
  • 10 Ritthaler U, Deng Y, Zhang Y. et al . Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease.  Am J Pathol. 1995;  146 688-694
    PubMedSearch in Google Scholar
  • 11 Schmidt A M, Stern D M. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes.  Trends Endocrinol Metab. 2000;  11 368-375
    PubMedSearch in Google Scholar
  • 12 Soulis T, Thallas V, Youssef S. et al . Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.  Diabetologia. 1997;  40 619-628
    CrossrefPubMedSearch in Google Scholar
  • 13 Stitt A W, He C, Vlassara H. Characterisation of advanced glycation end-product receptor complex in human vascular endothelial cells.  Viochem Biophys Res Commun. 1999;  256 549-556
    CrossrefPubMedSearch in Google Scholar
  • 14 Winocour P D. Platelet abnormalities in diabetes mellitus.  Diabetes. 1992;  41, Suppl 2 26-31
    PubMedSearch in Google Scholar
  • 15 World Health Organization diabetes mellitus: report of a WHO study group. WHO Tech Rep Ser No 727 1985: 9-10
    Search in Google Scholar

Mojca Globočnik Petrovič,MD, BSc 

Eye Clinic · University Medical Centre Ljubljana

Zaloška 29 a

1000 Ljubljana · Slovenia

Phone: + 386 1 522 1917

Email: mojca.globocnik@kclj.si